HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- chloro- 4- amino- 1,3,5- triazine- 6(5H)- one

Also Known As:

CATO

Networked: 10 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Triazines: 306
    - 2-chloro-4-amino-1,3,5-triazine-6(5H)-one: 10

Experts

1.	Guo, Kai: 1 article (09/2017)
2.	Ji, Qinghai: 1 article (09/2017)
3.	Li, Duanshu: 1 article (09/2017)
4.	Qian, Kai: 1 article (09/2017)
5.	Sun, Tuanqi: 1 article (09/2017)
6.	Wang, Zhuoying: 1 article (09/2017)
7.	Wu, Yi: 1 article (09/2017)
8.	Zheng, Xiaoke: 1 article (09/2017)
9.	Guo, K: 1 article (06/2017)
10.	Ji, Q H: 1 article (06/2017)

Related Diseases

1.	Thyrotoxicosis 08/01/2008 - "This study suggests that CATO LTT was well tolerated and more effective than oral MMI treatment in controlling thyrotoxicosis and promoting remission of GD in these Han Chinese patients."
2.	Hypothyroidism 08/01/2008 - "Compared with the MMI group (n 76), the CATO- treated group (n 78) had a significantly shorter median (range) time to restoration of normal serum thyroid hormone concentration (43 [12-150] vs 22 [7-60] days; P < 0.001), a significantly lower rate of recurrence of hyperthyroidism (309/1520 [20.3%] vs 193/1368 [14.1%] person-time; P < 0.001), a significantly lower drug hypothyroidism rate (185/1520 [12.2%] vs 54/1368 [3.9%] person-time; P < 0.001), and a higher remission rate (year 1:46/69 [66.7%] vs 65/72 [90.3%] patients, P 0.001; year 2:40/69 [58.0%] vs 60/72 [83.3%] patients, P - 0.001; year 3:34/69 [49.3%] vs 57/72 [79.2%] patients, P < 0.001; and year 4:30/69 [43.5%] vs 55/72 [76.4%] patients, P < 0.001). "
3.	Hyperthyroidism 08/01/2008 - "Compared with the MMI group (n 76), the CATO- treated group (n 78) had a significantly shorter median (range) time to restoration of normal serum thyroid hormone concentration (43 [12-150] vs 22 [7-60] days; P < 0.001), a significantly lower rate of recurrence of hyperthyroidism (309/1520 [20.3%] vs 193/1368 [14.1%] person-time; P < 0.001), a significantly lower drug hypothyroidism rate (185/1520 [12.2%] vs 54/1368 [3.9%] person-time; P < 0.001), and a higher remission rate (year 1:46/69 [66.7%] vs 65/72 [90.3%] patients, P 0.001; year 2:40/69 [58.0%] vs 60/72 [83.3%] patients, P - 0.001; year 3:34/69 [49.3%] vs 57/72 [79.2%] patients, P < 0.001; and year 4:30/69 [43.5%] vs 55/72 [76.4%] patients, P < 0.001). "
4.	Papillary Thyroid Microcarcinoma 09/12/2017 - "In this study, we retrospectively compared the application of two surveillance selection criteria in 1001 patients who had undergone surgical treatment of papillary thyroid microcarcinoma (PTMC): low-risk PTMC characteristics defined by Kuma Hospital and CATO consensus on PTMC management of active surveillance. " 06/07/2017 - "目的：探讨甲状腺微小乳头状癌(papillary thyroid microcarcinoma, PTMC)密切随访管理的合理性并探索适合随访患者的具体条件。方法：选取两种PTMC的随访适应证，即日本Kuma医院制订的随访标准和中国抗癌协会甲状腺癌专业委员会(CATO)制订的随访标准，分别应用于2008年1月至2010年12月复旦大学附属肿瘤医院PTMC术后的患者，回顾性分析比较各组患者临床病理特点和预后的差异。采用卡方分析和Fisher精确概率检验法比较各组临床病理特点，采用Kaplan－Meier生存分析描述各分组无病生存情况。结果： 778例PTMC患者满足条件纳入本研究中，其中共565例(72.6%)满足Kuma随访条件，112例(14.4%)满足CATO随访条件。根据标准，入组患者分为Kuma高危组(213例)、Kuma低危组(565例)和CATO高危组(666例)、CATO低危组(112例)。Kuma低危组与Kuma高危组相比，表现出较低的中央区淋巴结转移率，差异有统计学意义(30.6%比47.9%，P<0.05)。在评价CATO标准时，发现低危组的患者在多灶病变(6.3%比16.4%)、腺外侵犯(1.8%比7.5%)、中央区淋巴结转移(19.6%比38.0%)方面，均低于高危组，差异均有统计学意义(P值均<0.05)。评价各组预后，CATO低危组与CATO高危组相比，拥有明显较低的复发率(0.9%比6.0%，P<0.05)和更长的无病生存时间(P<0.05)。而Kuma低危组和Kuma高危组预后分析并未显示出差异。结论： CATO标准相对更为严格，该部分患者临床病理危险因素更少，预后更好。我们认为CATO密切随访标准筛选出的患者更加适合密切随访管理。."
5.	Respiratory Hypersensitivity 07/01/2013 - "In our previous study ('CATO') we showed preservation of lung function in asthmatic children, during 2 years of treatment that was guided by airway hyperresponsiveness (AHR). "

Related Drugs and Biologics

1.	Thyroid Hormones